Skip to content
Stock screener

CTY

Conviction 0HealthcareScan · Tue, Oct 20, 2026

City Therapeutics, Inc. (CTY) closed at $20.65 (-3.77%) on Oct 20, 2026. -7.8% from its 52-week high, -7.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.

CTY$20.65-3.77%
ResistanceSupportVol 14Insider buy
3 bars

Price chart, 3 bars from Fri, Oct 16, 2026 to Tue, Oct 20, 2026. Last close $20.65, high $23.88, low $20.18.

2
Oct 16Oct 19Oct 20
City Therapeutics, Inc.Pharmaceutical Preparations
Price20.65
Change-3.77%
Gap-1.72%
Rel volume0.02×
Avg volume573.99K
Avg $ vol12.75M
SMA 20—
SMA 50—
SMA 200—
Price vs 50—
Price vs 200—
MA stack—
50/200 cross—
Supertrend—
RSI (14)—
MACD hist—
MACD cross—
Stoch %K / %D— / —
ADX (14)—
+DI / −DI— / —
RSI divergence—
MACD divergence—
ATR %—
ADR %—
52w high22.40
52w low20.65
From 52w high-7.81%
Above 52w low+0.00%
New 52w highNo
SqueezeOff
Bollinger width—
%B—
Donchian pos—
Donchian high—
Donchian low—
AVWAP (52w high)—
vs AVWAP high—
AVWAP (52w low)—
vs AVWAP low—
OBV trend—
Chaikin MF (20)—
Today vs 20d0.02×
Avg vol (14d)—
Avg vol (20d)573.99K
Avg $ vol (20d)12.75M
Market cap—
RS Rating—
RS 3m (vs SPY)—
RS 6m (vs SPY)—
RS line new highNo
Trend template—
Technical rank—
1 week—
1 month—
3 months—
6 months—
1 year—
YTD-7.81%
P/E—
P/B—
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current—
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value—
Revenue—
Net income—
Gross profit—
Free cash flow—
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out—
Employees—
Listed—
Free float3.09M
Float %6.1%
Short interest—
Days to cover—
Short volume89.8%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction0 / 100
Pattern quality—
Tech rank—
Group rank—
Status laneNo active setup
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirm—

Recent news

Congress activity

Disclosed STOCK Act trades in CTY

All disclosures →
No recent disclosed trades by Congress in CTY. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CTY · open-market 2 buys

InsiderSideShares
NELSEN ROBERT
Director · Series B convertible preferred stock · 2026-10-19
Convert1.85M
ARCH Venture Partners XII, LLC
10% owner · Common Stock · 2026-10-19
Convert5.48M
ARCH Venture Partners XII, LLC
10% owner · Common Stock · 2026-10-19
Convert2.03M
ARCH Venture Partners XII, LLC
10% owner · Common Stock · 2026-10-19
Buy170K
ARCH Venture Partners XII, LLC
10% owner · Series Seed convertible preferred stock · 2026-10-19
Convert3M
ARCH Venture Partners XII, LLC
10% owner · Series A convertible preferred stock · 2026-10-19
Convert4.99M
ARCH Venture Partners XII, LLC
10% owner · Series B convertible preferred stock · 2026-10-19
Convert1.85M
NELSEN ROBERT
Director · Common Stock · 2026-10-19
Convert2.03M
NELSEN ROBERT
Director · Common Stock · 2026-10-19
Buy170K
NELSEN ROBERT
Director · Series Seed convertible preferred stock · 2026-10-19
Convert3M

SEC filings

EDGAR filings in CTY · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.